Estradiol Film, Extended Release
Product Images NDC 68968-3450

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Estradiol (NDC 68968-3450). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Noven Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Estradiol Figure 1)

FDA Label Image

Figure D (Estradiol Figure 10)

FDA Label Image

Figure E, F (Estradiol Figure 11)

FDA Label Image

Figure G (Estradiol Figure 12)

FDA Label Image

0.025 mg Pouch Label (Estradiol Figure 13)

0.025 mg Pouch Label (Estradiol Figure 13)
The text seems to be a product description of a hormonal transdermal patch containing 0.41mg of estradiol US that is applied twice-weekly. It comes in a package that contains 8 systems and should be immediately applied after removal from the pouch. The inactive components include acrylic adhesive, silicone adhesive, and others. The patch should be kept out of reach of children and stored at 20°C to 25°C. It includes dosage and administrative instructions, a barcode, and a pharmaceutical company's details.*
FDA Label Image

0.025 mg 8-count Carton Label (Estradiol Figure 14)

FDA Label Image

0.0375 mg Pouch Label (Estradiol Figure 15)

0.0375 mg Pouch Label (Estradiol Figure 15)
This is a description of a transdermal system that delivers 0.05 mg/day of Estradiol, an inactive component containing silicone adhesive, povidone, polyolefin laminating, polyester release, and 8 systems. The package insert has information on dosage and administration. The system is for transdermal use only and should be kept out of the reach of children. It is important to apply immediately upon removal from pouch and should not be stored unpouched. The recommended storage temperature is 20°C to 25°C.*
FDA Label Image

0.0375 mg 8-count Carton Label (Estradiol Figure 16)

FDA Label Image

0.050 mg Pouch Label (Estradiol Figure 17)

0.050 mg Pouch Label (Estradiol Figure 17)
This is a product description of Estradiol, a transdermal system designed for topical use twice-weekly. It contains 1.65 mg of estradiol USP and comes in a package of eight systems. The product's active components are acrylic adhesive, silicone adhesive, oleyl alcohol, dipropylene glycol, povidone, polyolefin laminate backing, polyester release liner. It should be stored at 20°C to 26°C and must be kept out of reach of children. The text also contains some unreadable characters and may be a result of errors.*
FDA Label Image

Layers (Estradiol Figure 2)

Layers (Estradiol Figure 2)
The product is an adhesive that contains estradiol and has a protective liner.*
FDA Label Image

Figure1 (Estradiol Figure 3)

Figure1 (Estradiol Figure 3)
The text describes a graph showing serum concentration in pg/mL over time (in days) for a medication that is administered at three different doses: 0.1mg/day, 0.05mg/day, and 0.25mg/day. The graph shows that the higher the dosage, the higher the serum concentration of the medication. However, without more information, it is impossible to determine what medication is being administered or why it is being administered at different doses.*
FDA Label Image

Figure2 (Estradiol Figure 4)

Figure2 (Estradiol Figure 4)
This appears to be a table displaying the results of a study with different measurements taken at week 4, week 8, and week 12. There are two groups being compared, one receiving a medication called Vivelle and the other receiving a placebo. The numbers in the table seem to represent the values for each measurement with their corresponding sample sizes. There is also a note indicating a statistically significant difference between the Vivelle and placebo groups.*
FDA Label Image

Figure3 (Estradiol Figure 5)

Figure3 (Estradiol Figure 5)
This table shows the percentage change from the baseline at different time points during a treatment duration of 104 weeks. The treatments compared are Vivelle at doses of 0.1mg/day, 0.025mg/day, 0.05mg/day, and 0.0375mg/day, as well as a placebo. However, no actual percentage values are provided, so the efficacy of the different treatments cannot be determined from this information alone.*
FDA Label Image

Figure4 (Estradiol Figure 6)

Figure4 (Estradiol Figure 6)
This text appears to be a table or chart that includes information on various treatments and their impact at different time intervals. It is not clear what the treatments are for or what the percentages and symbols indicate. The text does not provide enough context to generate a useful description.*
FDA Label Image

Figure A (Estradiol Figure 7)

FDA Label Image

Figure B (Estradiol Figure 8)

FDA Label Image

Figure C (Estradiol Figure 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.